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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the benefits and harms of antimicrobial mouthwashes and nasal sprays administered to patients with suspected or confirmed
COVID-19 infection in order to protect the healthcare workers (HCWs) caring for them.
To assess the benefits and harms of antimicrobial mouthwashes and nasal spray in improving outcomes for patients with suspected or
confirmed COVID-19 infection.
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B A C K G R O U N D
Description of the condition
The emergence of a novel coronavirus in late 2019 has resulted
in a global pandemic of an infectious condition - COVID-19. To
date, almost five million people have been reported to be infected,
with close to 300,000 deaths. Patients may be asymptomatic, or
they may have an illness with symptoms varying from mild to very
severe. Not all those who have the condition are tested for the
presence of the virus. No vaccine has been developed nor have
any therapeutic agents been shown to be eEective. Management
options are largely supportive. Many eEorts have focused on
prevention, using measures of social distancing and isolation.
Healthcare workers are at the forefront of this crisis, with repeated
exposure to individuals who are, or are very likely to be, infected,
and are therefore at risk themselves. Access to personal protective
equipment (PPE) is a key intervention which should reduce the
frequency of transmission of the infection to healthcare workers.
These workers are especially at risk when undertaking 'aerosol-
generating procedures' (AGPs). This is any medical, dental or
patient-care procedure that results in the production of airborne
particles (aerosols) from the upper aerodigestive tract (mouth,
nose, throat, oesophagus) and lower respiratory tract where the
virus is shedding. These can remain suspended in the air and travel
over a distance. They may cause infection if they are inhaled. Such
procedures therefore create the potential for airborne transmission
of infection.
This review is one of a set of three which consider two measures
that may protect healthcare workers and patients - both for
their own benefit, and to reduce the frequency of onward
transmission. These two measures are (1) the pre-procedural use of
mouthwashes and nasal sprays by patients, to reduce the risk that
any aerosol that they generate will infect healthcare workers, and
(2) the use of mouthwashes and nasal sprays by healthcare workers
pre- and post-exposure to patients with confirmed or suspected
infection to reduce the risk of acquiring such infection through their
mouth or nose. This particular review focuses on the treatment
of patients with suspected or confirmed COVID-19 infection and
the protection of HCWs treating them. It evaluates the use of
mouthwashes and nasal sprays administered to patients alone ((1)
above) without any intervention to the HCWs ((2) above). (The
other two reviews will focus on a) the protection of HCWs treating
patients with suspected or confirmed COVID-19 infection (Burton
2020a) and b) the protection of HCWs when they are undertaking
AGPs on patients who are not known to have, or suspected of
having, COVID-19 infection (Burton 2020b)).
Description of the intervention
Mouthwashes are oral rinsing solutions that are in common use
to manage halitosis, prevent tooth decay and reduce plaque
formation. In some countries they are recommended as a
hygiene measure during the regular cold and flu season. Many
mouthwashes with some antimicrobial activity can be purchased
over the counter, and others are available on prescription. The
antimicrobial agents and eEectiveness vary and whilst most have
some antibacterial properties a few are also antiviral.
Similar topical antimicrobial solutions may be administered via
the nose using a nasal spray, or by direct irrigation or douching
(administered by sniEing a solution through each nostril and
spitting it out).
How the intervention might work
There has been considerable interest in the use of nasal irrigation
or oral rinses to prevent transmission of upper respiratory tract
infections (URTI) caused by viruses, or to alleviate their symptoms.
Transmission of such disease occurs by the inhalation of small
droplets containing viral particles, or by direct transfer (for example
from surfaces, to hands, and then to the face, mouth and nose).
Rinsing the mouth and/or nose may eradicate viral particles
completely - preventing transmission to that individual - or reduce
the viral load that the individual is exposed to. This may prevent
the disease developing in that individual or reduce the severity
of it. Gargles that have been investigated for their ability to
reduce viral transmission, include tea (or components of tea) (Ide
2016), water (Goodall 2014) and povidone iodine (Kitamura 2007;
Satomura 2005). Other mouthwashes in common use, including
hydrogen peroxide and chlorhexidine, may also have antiviral
activity (Bernstein 1990).
Nasal irrigation with topical antimicrobial solutions similar to those
used as mouthwashes has also been investigated. Carrageenan, a
carbohydrate found in red seaweed, has been trialled as an antiviral
nasal spray. Studies have identified a decrease in the nasal viral
load from URTI, but results on symptomatic improvement have
been mixed (Eccles 2010; Eccles 2015; Fazekas 2012; Ludwig 2013).
Given the new emergence of COVID-19, the eEicacy of nasal or oral
irrigation fluids against this disease is not yet known. However,
activity against similar novel coronaviruses (such as those
responsible for severe acute respiratory syndrome (SARS) and
Middle East respiratory syndrome (MERS)) has been demonstrated
for some preparations (Eggers 2015; Kariwa 2006). Gargle solutions
of povidone iodine have been shown to be active against the
coronaviruses causing both MERS and SARS in vitro (Eggers 2018;
Kariwa 2006).
How the intervention might cause harm
Use of mouthwash or nasal irrigation has the potential to cause a
variety of adverse eEects. In common with many treatments, there
is the possibility of irritation or allergic reaction to components of
the product. A key concern for any agent used intranasally is the
potential for long-term damage resulting in anosmia (loss of sense
of smell). However, anosmia may also be a possible symptom of
COVID-19 infection.
There is also a concern that local application of antimicrobials
will disrupt the normal nasal and oral microbiota. The microbiome
is increasingly recognised as playing a vital role in preventing
colonisation with invading pathogens, supporting the host immune
system and a variety of other functions (Kilian 2016; Man 2017).
Alteration of this delicate environment could result in significant
health problems.
Other potential harms are related to specific irrigation fluids. These
include the risk of excess iodine ingestion from iodine-containing
gargle solution or staining of teeth with chlorhexidine.
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O B J E C T I V E S
To assess the benefits and harms of antimicrobial mouthwashes
and nasal sprays administered to patients with suspected or
confirmed COVID-19 infection in order to protect the healthcare
workers (HCWs) caring for them.
To assess the benefits and harms of antimicrobial mouthwashes
and nasal spray in improving outcomes for patients with suspected
or confirmed COVID-19 infection.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This is a question that urgently requires evidence, however at the
present time we do not anticipate finding many completed RCTs.
We will therefore include following types of studies:
• randomised controlled trials (RCTs);
• quasi-RCTs;
• non-randomised controlled trials;
• prospective cohort studies;
• retrospective cohort studies;
• cross-sectional studies;
• controlled before-and-aKer studies.
There is no minimum duration for the studies.
Types of participants





Any antimicrobial mouthwash and/or nasal spray (alone or in
combination) at any concentration, delivered with any frequency or
dosage to suspected/confirmed COVID-19 patients.
Comparator
No treatment or saline or water.
Types of outcome measures
We will analyse the following outcomes in the review, but we will
not use them as a basis for including or excluding studies.
We will assess the primary outcomes at a minimum of two weeks.
For all other outcomes, there will be no minimum follow-up.
For all outcomes we will accept the method of measurement used
by the triallists but will take a critical approach to the value of each
measure.
Primary outcomes
• RECOVERY* outcomes in patients (www.recoverytrial.net):
* mortality;
* hospitalisation status;
* use of ventilation;
* use of renal dialysis or haemofiltration.
• Incidence of symptomatic or test-positive COVID-19 infection in
HCWs.
• Significant adverse event: anosmia (or disturbance in sense of
smell).
Secondary outcomes
• Change in COVID-19 viral load in patients.
• COVID-19 viral content of aerosol (when present).
• Other adverse events: changes in microbiome in oral cavity,
nasal cavity, oro- or nasopharynx.
• Other adverse events: allergy, irritation/burning of nasal, oral
or oropharyngeal mucosa (e.g. erosions, ulcers, bleeding),
long-term staining of mucous membranes or teeth, accidental
ingestion.
Search methods for identification of studies
The Cochrane ENT and Oral Health Information Specialists will
conduct systematic searches for all human studies. There will be
no language, publication year or publication status restrictions. We
may contact original authors for clarification and further data if
trial reports are unclear and we will arrange translations of papers
where possible.
Electronic searches
Published, unpublished and ongoing studies will be identified by
searching the following databases from their inception:
• the Cochrane Central Register of Controlled Trials (CENTRAL)
(search via the Cochrane Register of Studies to date);
• Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
(1946 to date);
• Ovid EMBASE (1974 to date);
• World Health Organization (WHO) COVID-19 Global literature
on coronavirus disease https://search.bvsalud.org/global-
literature-on-novel-coronavirus-2019-ncov (search to date);
• Cochrane COVID-19 Study Register https://
covid-19.cochrane.org/ (search via the Cochrane Register of
Studies to date).
The subject strategies for databases will be modelled on the search
strategy designed for Ovid MEDLINE (Appendix 1).
Searching other resources
We will not perform a separate search for adverse eEects. We will
consider adverse eEects described in included studies only.
We will not perform a separate search for pre-print publications. We
will identify and report as awaiting assessment any we identify from
the sources above that meet our inclusion criteria but we will not
extract the data until their publication in a peer-reviewed journal.
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We will make eEorts to identify full-text papers regardless
of language of publication and endeavour to seek help with
translation; however, we will not hold up the rapid review process.
Any papers that we are unable to source quickly or are unable to get
translated will be listed as awaiting assessment.
Data collection and analysis
Selection of studies
AMG, HW (and others) will perform screening using Covidence.
All titles and abstracts identified through the searching will be
screened independently by two review authors. Discrepancies will
be discussed and, where necessary, a third review author will be
included. Where uncertainties remain, we will retrieve the full text
for clarification. The full text of potentially relevant articles will
again be screened by two review authors, independently.
All decisions regarding exclusion of studies, taken during screening,
will be documented and outlined in the final report with a list of
excluded studies.
Data extraction and management
AMG, HW (and others) will perform data extraction using a
predefined data extraction form (Word/Excel). Data will be limited
to a minimal set of required data items following input from content
experts and methodologists.
A single review author will undertake data extraction and a second
review author will check the completeness/accuracy of the data
extraction. Discrepancies will be discussed and taken to a third
review author as required.
We will contact study authors for missing outcome data, or where
there are conflicting data reported across multiple sources for a
single study.
Assessment of risk of bias in included studies
We will undertake risk of bias assessment at the same time as data
extraction. We will use the Cochrane RCT 'Risk of bias' tool and the
ROBINS-I tool for non-randomised studies. We will exclude studies
judged to be at critical risk of bias from analysis.
As for data extraction, all judgements will be checked by a second
review author. Discrepancies will be discussed and taken to a third
review author as required.
Measures of treatment e:ect
We will present dichotomous data as risk ratios (RR) with
corresponding 95% confidence intervals (CIs). However, if we
identify case-control studies relevant to the review questions, we
will consider the use of odds ratio as the appropriate estimate of
eEect.
We will present continuous data as mean diEerence (MD) with
corresponding 95% CIs. Where necessary, we will convert outcome
data to the same unit of measurement.
Where data are extracted from non-RCTs, we will use adjusted
eEects where available. If multiple adjusted eEects are reported,
then we will choose the one judged to minimise the risk of bias due
to confounding.
Unit of analysis issues
The unit of analysis will be the participant. Any cluster-RCTs would
need to have analysed results taking account of the clustering
present in the data, otherwise we will use the methods outlined in
Section 16.3.4 of the Cochrane Handbook for Systematic Reviews of
Interventions in order to perform an approximately correct analysis
(Higgins 2011). We will include studies with multiple treatment
arms as appropriate, ensuring that there is no double counting of
patients in any meta-analysis.
Dealing with missing data
We will contact study authors for missing outcome data. Where
appropriate, we will use the methods outlined in Section 7.7.3 of
the Cochrane Handbook for Systematic Reviews of Interventions in
order to estimate missing standard deviations (Higgins 2011). We
will not use any further statistical methods or carry out any further
imputation to account for missing data.
Assessment of heterogeneity
We will assess statistical heterogeneity initially through inspection
of forest plots. We will use the Chi2 for heterogeneity, with P = 0.10,
to indicate substantial heterogeneity (acknowledging that this has
low power if there is a small sample size or few studies).
We will also use the I2 statistic, following the interpretation
recommended in the Cochrane Handbook for Systematic Reviews
of Interventions (0% to 40% might not be important; 30% to
60% may represent moderate heterogeneity; 50% to 90% may
represent substantial heterogeneity; 75% to 100% considerable
heterogeneity) (Handbook 2019). We will be cautious in
interpreting the I2 value, as this may be uncertain when there are
few studies.
We will explore potential sources of heterogeneity among study
results. Sources may include: clinical setting, clinical procedure.
Assessment of reporting biases
Where there are 10 or more studies in a meta-analysis, we will
assess possible publication bias by visually inspecting a funnel plot
for asymmetry.
Data synthesis
We will make a judgement regarding the clinical and
methodological heterogeneity; only where there is deemed to be
reasonable homogeneity across studies will we consider statistical
pooling of data. If appropriate, we will conduct statistical pooling
of data from RCTs, followed by data from non-RCTs. We will not
undertake pooling across diEerent types of study designs.
We will use a random-eEects model.
Lastly, we will undertake a narrative synthesis, encompassing
findings from both RCT and non-RCT studies.
Subgroup analysis and investigation of heterogeneity
Where data are available, we will conduct subgroup analyses,
where possible, according to clinical procedure (AGP versus non-
AGP) and clinical setting (e.g. inpatient, outpatient, dental, ENT).
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Sensitivity analysis
We will undertake sensitivity analysis excluding studies at high risk
of bias.
Summary of findings and assessment of the certainty of the
evidence
We will use the GRADE approach and present 'Summary of findings'
tables for all comparisons and all outcomes.
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A P P E N D I C E S
Appendix 1. Search strategy
 
 
1 ("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel
coronavirus" or "novel corona virus" or "SARS CoV-2" or "2019-novel CoV" or ncov19 or
ncov-19).ab,ti.
8083
2 (Wuhan and (coronavirus or "corona virus")).ab,ti. 656
3 ((coronavirus or "corona virus") adj3 "2019").ab,ti. 1474
4 (wuhan adj2 (disease or virus)).ab,ti. 34
5 ("LAMP assay" or "COVID-19" or "COVID-19 drug treatment" or "COVID-19 diagnostic test-
ing" or "COVID-19 serotherapy" or "COVID-19 vaccine" or "severe acute respiratory syn-
drome coronavirus 2" or "spike glycoprotein, COVID-19 virus").os.
981
6 1 or 2 or 3 or 4 or 5 8284
7 exp Animals/ 23104204
8 exp Humans/ 18413197
9 7 not 8 4691007
10 (editorial or comment or letter or newspaper article).pt. 1847573
11 9 or 10 6471247
12 6 not 11 5782
13 exp Mouthwashes/ 14306
14 exp Nasal Sprays/ 501
15 exp Nasal Lavage/ 1356
16 (Mouthwash* or gargl* or mouthrins*).ab,ti. 4510
17 ((oral or mouth or nasal or nose or nasopharyngeal or larynx* or pharynx* or intranasal)
adj3 (spray* or douch* or irrigat* or lavag* or wash or rins* or decontaminat* or aerosol or
mist or clean*)).ab,ti.
10846
18 exp Chlorhexidine/ 8260
19 exp Povidone-Iodine/ 2816
20 exp Cetylpyridinium/ 939
21 exp Hexetidine/ 148
22 exp Anti-Infective Agents, Local/ 230412
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23 exp Hydrogen Peroxide/ 57593
24 exp Carbamide Peroxide/ 1055
25 exp Triclosan/ 2807
26 exp Oils, volatile/ 14097
27 exp Plant oils/ 36092
28 Menthol/ 1915
29 Lavandula/ 461
30 Thymus plant/ 1410
31 Mentha piperita/ 378
32 Eugenol/ 2260
33 Cinnamomum verum/ 776
34 Muramidase/ 22670
35 Lactoferrin/ 5996
36 Glucose oxidase/ 5060
37 Lactoperoxidase/ 1333
38 (povidone or chlorhexidine or CHX or PVP or Polyvinylpyrrolidone or Betadine* or Provi-
dine* or Disadine* or Isodine* or Pharmadine* or Alphadine* or Betaisodona or Tubulicid
or Novalsan or Sebidin or MK-412A or MK412A).ab,ti.
24280
39 (Chlorhexamed or Corsodyl or Curasept or Dyna-Hex or Eludril or Gibitan or Hexidine or
Hibiclens or Hibident or Hibiscrub or Hibisol or Hibitane or Peridex or avagard).ab,ti.
403
40 (Hexadecylpyridinium or Cetylpyridium or Biosept or Ceepryn or Cetamium or Catami-
um or Sterogenol or Dobendan or Merocets or Pristacin or Pyrisept or Angifonil or Cety-
lyre).ab,ti.
154
41 (Vagi-Hex or Vagi Hex or VagiHex or Oraldene or Hexigel or Steri-sol or Steri sol or Hextril
or Oraldine or Oralspray or Hexoral or Bactidol or Elsix or Duranil or Doreperol or Hexeti-
dine).ab,ti.
141
42 (Hydrogen Peroxide or H2O2 or Hydroperoxide or Superoxol or Oxydol or Perhydrol or
Urea Peroxide or Perhydrol Urea).ab,ti.
91131
43 (Methyl salicylate or methylsalicylate or Rheumabal or Metsal Liniment or Hewedolor or
Linsal).ab,ti.
1103
44 (Tricolsan or Hydroxydiphenyl or trichlorodiphenyl or Clearasil or Cliniclean or Irgasan or
Trisan or Oxy Skin Wash or pHisoHex or Sapoderm or Tersaseptic or Aquasept or Ster-Zac
or Manusept or Microshield).ab,ti.
333
45 ((Spray* or douch* or irrigat* or rins* or wash* or lavag* or intranasal* or topical) adj3 (an-
timicrobial or anti-microbial or disinfect* or antisept* or anti-infect*)).ab,ti.
2880
  (Continued)
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46 ("essential oil$" or "plant oil$" or menthol or menthyl or (mint adj2 oil$) or lavender or
thyme or peppermint or "mentha piperita" or eugenol or eucalyptus or "blue gum$" or
cajeput or clove or cinnamon).ab,ti.
30191
47 (muramidase or lysozyme$ or leftose or lactoferrin or lactotransferrin or "glucose oxi-
dase" or lactoperoxidase or "saliva substitute").ab,ti.
42128
48 (Listerine or Biotene).ab,ti. 361
49 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or
29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or
45 or 46 or 47 or 48
422052
50 12 and 49 14
  (Continued)
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